Armata Pharmaceuticals receives $4.65M of funding from DoD

Armata Pharmaceuticals (ARMP) announced that it has received an additional $4.65M of non-dilutive funding pursuant to a previously announced Department of Defense award, received through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, currently totaling $26.2M, was awarded to Armata to support clinical development of its optimized phage candidate, AP-SA02, as a potential treatment for complicated Staphylococcus aureus bacteremia. The additional $4.65M will be used to support Phase 2a study close out activities as well as for the preparation and execution of an end-of-phase 2 meeting with the U.S. FDA. Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial.